Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC)
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2490
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC) ; volume:14 ; number:1 ; day:25 ; month:7 ; year:2014 ; pages:1-8 ; date:12.2014
BMC urology ; 14, Heft 1 (25.7.2014), 1-8, 12.2014
- Creator
-
Gupta, Eva
- Contributor
-
Guthrie, Troy
Tan, Winston
SpringerLink (Online service)
- DOI
-
10.1186/1471-2490-14-55
- URN
-
urn:nbn:de:1111-2016071626034
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:48 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Gupta, Eva
- Guthrie, Troy
- Tan, Winston
- SpringerLink (Online service)
Other Objects (12)
Ureter metastatic castration-resistant prostate cancer: a case report
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Novel therapies are changing treatment paradigms in metastatic prostate cancer
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
The changing landscape of hormonal therapy in castration-resistant prostate cancer
Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer
Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey
Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
Ureter metastatic castration-resistant prostate cancer: a case report
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Novel therapies are changing treatment paradigms in metastatic prostate cancer
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
The changing landscape of hormonal therapy in castration-resistant prostate cancer
Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer
Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey
Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
Ureter metastatic castration-resistant prostate cancer: a case report
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Novel therapies are changing treatment paradigms in metastatic prostate cancer
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
The changing landscape of hormonal therapy in castration-resistant prostate cancer
Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer
Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey
Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer